FDA Approves the First Treatment for ADPKD

Living with PKD | Newly Diagnosed
Back to Search
Recorded April 2018
In this webinar, learn about JYNARQUE™ (tolvaptan), the new FDA-approved treatment for ADPKD. Hosted by Ronald Perrone, M.D., Associate Chief, Division of Nephrology at Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. 

Related Resources

ARPKD EL-PFDD 2023

ARPKD EL-PFDD 2023

What to Expect from the ARPKD EL-PFDD Meeting On August 29, 2023 the PKD Foundation will hold its first ever Externally Led Patient-focused Drug Development (EL-PFDD) Meeting on Autosomal Recessive PKD (ARPKD) and Congenital Hepatic Fibrosis (CHF). Should you attend the meeting? What should you...

ADPKD Registry Annual Report 2022

ADPKD Registry Annual Report 2022

The PKDF Research team is excited to expand the features available in the ADPKD Registry in summer 2023. This project has been carefully planned and executed with our patients at the center. The last few years have been spent building the largest ADPKD patient-reported outcomes dataset.